PAO Group has executed a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA).
Recently PAOG acquired RespRx from Kali-Extracts and began to transform the company into cannabis biopharmaceutical development operation.
RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "Method and Apparatus for Processing Herbaceous Plant Materials Including the Cannabis Plant."
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
As previously announced, and in addition to the CRO agreement, PAOG continues to develop pharmaceutical research and development relationships in Puerto Rico's burgeoning, recently reinvigorated pharmaceutical industry.
Part of PAOG's pharmaceutical development strategy includes the development of a proprietary hemp cultivar. In addition to acquiring RespRx from KALY, PAOG recently acquired a hemp cultivation business from Puration. PAOG is building a partnership with PURA in conjunction with PAOG's new hemp cultivation business. PAOG has announced working with PURA's new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.